Catathrenia under @entity15221 in XXXX with @entity2725 .

@entity1 @entity2725 @entity308 @entity387 @entity15221 @entity27 @entity2724 @entity4939
PURPOSE: This study aims to report on catathrenia occurring in @entity2724 with @entity2725 (NC) @entity1 under @entity15221 (SO) treatment. Catathrenia is a @entity4939 characterized by groaning and an abnormal respiratory pattern during sleep. METHODS: Fifty-one @entity1 with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any @entity387 ( @entity387 ). To avoid risks due to a possible central respiratory control @entity308 by SO, all @entity1 with @entity27 ( @entity27 ) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2  months of treatment with SO, all @entity1 underwent a follow-up overnight PSG to investigate possible newly occurring @entity387 . They also underwent a semi-structured clinical interview to monitor other potential SO side effects. RESULTS: At baseline, four out of 51 @entity1 showed simple snoring, and eight, mild to severe @entity27 . After a titration PSG night, @entity1 with @entity27 received a nCPAP device. After 2  months of SO treatment, 28 @entity1 (54.9%) showed SO-related side effects, including @entity387 in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven @entity1 (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of @entity27 . CONCLUSIONS: Catathrenia should be considered a possible side effect in NC @entity1 under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
